Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial.

Hacker UT, Hasenclever D, Linder N, Stocker G, Chung HC, Kang YK, Moehler M, Busse H, Lordick F.

J Cachexia Sarcopenia Muscle. 2019 Aug 28. doi: 10.1002/jcsm.12484. [Epub ahead of print]

2.

Pseudoexfoliation syndrome: analysis of systemic comorbidities of 325 PEX-positive patients compared with 911 PEX-negative patients.

Scharfenberg E, Rauscher FG, Meier P, Hasenclever D.

Graefes Arch Clin Exp Ophthalmol. 2019 Aug 16. doi: 10.1007/s00417-019-04438-4. [Epub ahead of print]

PMID:
31420731
3.

High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact.

Obermannova R, Valik D, Hasenclever D, Zdrazilova-Dubska L, Hacker U, Demlova R, Selingerova I, Lordick F.

Eur J Cancer. 2019 Jul;116:107-113. doi: 10.1016/j.ejca.2019.05.011. Epub 2019 Jun 10.

PMID:
31195354
4.

Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients - the study design of the LIBERAL-Trial.

Meybohm P, Lindau S, Treskatsch S, Francis R, Spies C, Velten M, Wittmann M, Gueresir E, Stoppe C, Kowark A, Coburn M, Selleng S, Baschin M, Jenichen G, Meersch M, Ermert T, Zarbock A, Kranke P, Kredel M, Helf A, Laufenberg-Feldmann R, Ferner M, Wittenmeier E, Gürtler KH, Kienbaum P, de Abreu MG, Sander M, Bauer M, Seyfried T, Gruenewald M, Choorapoikayil S, Mueller MM, Seifried E, Brosteanu O, Bogatsch H, Hasenclever D, Zacharowski K; LIBERAL Collaboration Group.

Trials. 2019 Feb 4;20(1):101. doi: 10.1186/s13063-019-3200-3.

5.

Genome-wide association study of myocardial infarction, atrial fibrillation, acute stroke, acute kidney injury and delirium after cardiac surgery - a sub-analysis of the RIPHeart-Study.

Westphal S, Stoppe C, Gruenewald M, Bein B, Renner J, Cremer J, Coburn M, Schaelte G, Boening A, Niemann B, Kletzin F, Roesner J, Strouhal U, Reyher C, Laufenberg-Feldmann R, Ferner M, Brandes IF, Bauer M, Kortgen A, Stehr SN, Wittmann M, Baumgarten G, Struck R, Meyer-Treschan T, Kienbaum P, Heringlake M, Schoen J, Sander M, Treskatsch S, Smul T, Wolwender E, Schilling T, Degenhardt F, Franke A, Mucha S, Tittmann L, Kohlhaas M, Fuernau G, Brosteanu O, Hasenclever D, Zacharowski K, Meybohm P; RIPHeart-Study Collaborators.

BMC Cardiovasc Disord. 2019 Jan 24;19(1):26. doi: 10.1186/s12872-019-1002-x.

6.

Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.

Kurch L, Hasenclever D, Kluge R, Georgi T, Tchavdarova L, Golombeck M, Sabri O, Eggert A, Brenner W, Sykora KW, Bengel FM, Rossig C, Körholz D, Schäfers M, Feuchtinger T, Bartenstein P, Ammann RA, Krause T, Urban C, Aigner R, Gattenlöhner S, Klapper W, Mauz-Körholz C.

Pediatr Blood Cancer. 2019 Mar;66(3):e27539. doi: 10.1002/pbc.27539. Epub 2018 Nov 14.

PMID:
30426671
7.

Loss of paraspinal muscle mass is a gender-specific consequence of cirrhosis that predicts complications and death.

Engelmann C, Schob S, Nonnenmacher I, Werlich L, Aehling N, Ullrich S, Kaiser T, Krohn S, Herber A, Sucher R, Bartels M, Surov A, Hasenclever D, Kahn T, Seehofer D, Moche M, Berg T.

Aliment Pharmacol Ther. 2018 Dec;48(11-12):1271-1281. doi: 10.1111/apt.15026. Epub 2018 Nov 11.

PMID:
30417398
8.

Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).

Pouleur AC, Anker S, Brito D, Brosteanu O, Hasenclever D, Casadei B, Edelmann F, Filippatos G, Gruson D, Ikonomidis I, Lhommel R, Mahmod M, Neubauer S, Persu A, Gerber BL, Piechnik S, Pieske B, Pieske-Kraigher E, Pinto F, Ponikowski P, Senni M, Trochu JN, Van Overstraeten N, Wachter R, Balligand JL.

ESC Heart Fail. 2018 Oct;5(5):830-841. doi: 10.1002/ehf2.12306. Epub 2018 Jun 22. Erratum in: ESC Heart Fail. 2018 Dec;5(6):1199.

9.

Antibody Concentrations Decrease 14-Fold in Children With Celiac Disease on a Gluten-Free Diet but Remain High at 3 Months.

Petroff D, Wolf J, Richter T, Auth MKH, Uhlig HH, Laass MW, Lauenstein P, Krahl A, Händel N, de Laffolie J, Hauer AC, Heiduk M, Flemming G, Schmidt A, Hasenclever D, Mothes T.

Clin Gastroenterol Hepatol. 2018 Sep;16(9):1442-1449.e5. doi: 10.1016/j.cgh.2018.04.008. Epub 2018 Apr 12.

10.

18F-FDG PET Response of Skeletal (Bone Marrow and Bone) Involvement After Induction Chemotherapy in Pediatric Hodgkin Lymphoma: Are Specific Response Criteria Required?

Georgi TW, Kluge R, Kurch L, Chavdarova L, Hasenclever D, Stoevesandt D, Pelz T, Landman-Parker J, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Fosså A, Balwierz W, Attarbaschi A, Ammann RA, Pears J, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Daw S, Baumann J, Körholz D, Sabri O, Mauz-Körholz C.

J Nucl Med. 2018 Oct;59(10):1524-1530. doi: 10.2967/jnumed.117.205633. Epub 2018 Apr 13.

11.

RIPHeart (Remote Ischemic Preconditioning for Heart Surgery) Study: Myocardial Dysfunction, Postoperative Neurocognitive Dysfunction, and 1 Year Follow-Up.

Meybohm P, Kohlhaas M, Stoppe C, Gruenewald M, Renner J, Bein B, Albrecht M, Cremer J, Coburn M, Schaelte G, Boening A, Niemann B, Sander M, Roesner J, Kletzin F, Mutlak H, Westphal S, Laufenberg-Feldmann R, Ferner M, Brandes IF, Bauer M, Stehr SN, Kortgen A, Wittmann M, Baumgarten G, Meyer-Treschan T, Kienbaum P, Heringlake M, Schoen J, Treskatsch S, Smul T, Wolwender E, Schilling T, Fuernau G, Bogatsch H, Brosteanu O, Hasenclever D, Zacharowski K; RIPHeart (Remote Ischemic Preconditioning for Heart Surgery) Study Collaborators.

J Am Heart Assoc. 2018 Mar 26;7(7). pii: e008077. doi: 10.1161/JAHA.117.008077.

13.

Reply to: Laffon and Marthan "FDG PET for therapy monitoring in Hodgkin's and non-Hodgkin's lymphomas: qPET versus rPET".

Kluge R, Barrington S, Kurch L, Hasenclever D.

Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2331-2332. doi: 10.1007/s00259-017-3826-x. Epub 2017 Sep 22. No abstract available.

PMID:
28939986
14.

Risk-adapted monitoring is not inferior to extensive on-site monitoring: Results of the ADAMON cluster-randomised study.

Brosteanu O, Schwarz G, Houben P, Paulus U, Strenge-Hesse A, Zettelmeyer U, Schneider A, Hasenclever D.

Clin Trials. 2017 Dec;14(6):584-596. doi: 10.1177/1740774517724165. Epub 2017 Aug 8.

15.

Remote ischaemic preconditioning for coronary artery bypass grafting (with or without valve surgery).

Benstoem C, Stoppe C, Liakopoulos OJ, Ney J, Hasenclever D, Meybohm P, Goetzenich A.

Cochrane Database Syst Rev. 2017 May 5;5:CD011719. doi: 10.1002/14651858.CD011719.pub3. Review.

16.

Validation of Antibody-Based Strategies for Diagnosis of Pediatric Celiac Disease Without Biopsy.

Wolf J, Petroff D, Richter T, Auth MKH, Uhlig HH, Laass MW, Lauenstein P, Krahl A, Händel N, de Laffolie J, Hauer AC, Kehler T, Flemming G, Schmidt F, Rodrigues A, Hasenclever D, Mothes T.

Gastroenterology. 2017 Aug;153(2):410-419.e17. doi: 10.1053/j.gastro.2017.04.023. Epub 2017 Apr 28.

17.

Do paraneoplastic changes in diffuse FDG organ uptake predict relapse? - Wait for confirmation study : Reply to Jorgov et al. Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1220--30.

Kluge R, Kurch L, Georgi T, Hasenclever D.

Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):170-171. No abstract available.

PMID:
27761620
18.

Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma.

Hohloch K, Zeynalova S, Chapuy B, Pfreundschuh M, Loeffler M, Ziepert M, Feller AC, Trümper L, Hasenclever D, Wulf G, Schmitz N.

Ann Hematol. 2016 Jun;95(7):1121-8. doi: 10.1007/s00277-016-2671-5. Epub 2016 May 11.

PMID:
27165090
19.

Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma.

Kluge R, Chavdarova L, Hoffmann M, Kobe C, Malkowski B, Montravers F, Kurch L, Georgi T, Dietlein M, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Wilson L, Bergstraesser E, Sabri O, Mauz-Körholz C, Körholz D, Hasenclever D.

PLoS One. 2016 Mar 10;11(3):e0149072. doi: 10.1371/journal.pone.0149072. eCollection 2016.

20.

Remote Ischemic Preconditioning and Cardiac Surgery.

Meybohm P, Hasenclever D, Zacharowski K.

N Engl J Med. 2016 Feb 4;374(5):491. doi: 10.1056/NEJMc1514509. No abstract available.

PMID:
26840140
21.

Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma.

Rösch K, Scholz M, Hasenclever D.

Leuk Lymphoma. 2016 Jul;57(7):1697-708. doi: 10.3109/10428194.2015.1110746. Epub 2015 Dec 15.

PMID:
26666299
22.

A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery.

Meybohm P, Bein B, Brosteanu O, Cremer J, Gruenewald M, Stoppe C, Coburn M, Schaelte G, Böning A, Niemann B, Roesner J, Kletzin F, Strouhal U, Reyher C, Laufenberg-Feldmann R, Ferner M, Brandes IF, Bauer M, Stehr SN, Kortgen A, Wittmann M, Baumgarten G, Meyer-Treschan T, Kienbaum P, Heringlake M, Schön J, Sander M, Treskatsch S, Smul T, Wolwender E, Schilling T, Fuernau G, Hasenclever D, Zacharowski K; RIPHeart Study Collaborators.

N Engl J Med. 2015 Oct 8;373(15):1397-407. doi: 10.1056/NEJMoa1413579. Epub 2015 Oct 5.

23.

Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group.

Mauz-Körholz C, Lange T, Hasenclever D, Burkhardt B, Feller AC, Dörffel W, Kluge R, Vordermark D, Körholz D.

Klin Padiatr. 2015 Nov;227(6-7):314-21. doi: 10.1055/s-0035-1559664. Epub 2015 Sep 10. Review.

PMID:
26356319
24.

The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer.

Wichmann G, Rosolowski M, Krohn K, Kreuz M, Boehm A, Reiche A, Scharrer U, Halama D, Bertolini J, Bauer U, Holzinger D, Pawlita M, Hess J, Engel C, Hasenclever D, Scholz M, Ahnert P, Kirsten H, Hemprich A, Wittekind C, Herbarth O, Horn F, Dietz A, Loeffler M; Leipzig Head and Neck Group (LHNG).

Int J Cancer. 2015 Dec 15;137(12):2846-57. doi: 10.1002/ijc.29649. Epub 2015 Jul 6.

25.

Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial.

Mauz-Körholz C, Hasenclever D, Holzendorf V, Bernstädt M, Jürgens H, Burdach S, Eggert A, Berthold F, Müller HL, Frühwald MC, Klingebiel T, Metzler M, Körholz D.

Leuk Lymphoma. 2015 May;56(5):1308-14. doi: 10.3109/10428194.2014.961011. Epub 2014 Oct 9.

PMID:
25204374
26.

Sources of variability in FDG PET imaging and the qPET value: reply to Laffon and Marthan.

Hasenclever D, Kurch L, Kluge R.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2155-7. doi: 10.1007/s00259-014-2880-x. No abstract available.

PMID:
25112397
27.

Genomic and epigenomic co-evolution in follicular lymphomas.

Loeffler M, Kreuz M, Haake A, Hasenclever D, Trautmann H, Arnold C, Winter K, Koch K, Klapper W, Scholtysik R, Rosolowski M, Hoffmann S, Ammerpohl O, Szczepanowski M, Herrmann D, Küppers R, Pott C, Siebert R; HaematoSys-Project.

Leukemia. 2015 Feb;29(2):456-63. doi: 10.1038/leu.2014.209. Epub 2014 Jul 16.

PMID:
25027518
28.

Assessing laboratory performance in Trichinella ring trials.

Petroff D, Hasenclever D, Makrutzki G, Riehn K, Lücker E.

Parasitol Res. 2014 Aug;113(8):2837-43. doi: 10.1007/s00436-014-3944-3. Epub 2014 May 18.

PMID:
24838905
29.

Antibodies in the diagnosis of coeliac disease: a biopsy-controlled, international, multicentre study of 376 children with coeliac disease and 695 controls.

Wolf J, Hasenclever D, Petroff D, Richter T, Uhlig HH, Laaß MW, Hauer A, Stern M, Bossuyt X, de Laffolie J, Flemming G, Villalta D, Schlumberger W, Mothes T.

PLoS One. 2014 May 15;9(5):e97853. doi: 10.1371/journal.pone.0097853. eCollection 2014. Erratum in: PLoS One. 2014;9(8):e105230.

30.

qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma.

Hasenclever D, Kurch L, Mauz-Körholz C, Elsner A, Georgi T, Wallace H, Landman-Parker J, Moryl-Bujakowska A, Cepelová M, Karlén J, Álvarez Fernández-Teijeiro A, Attarbaschi A, Fosså A, Pears J, Hraskova A, Bergsträsser E, Beishuizen A, Uyttebroeck A, Schomerus E, Sabri O, Körholz D, Kluge R.

Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1301-8. doi: 10.1007/s00259-014-2715-9. Epub 2014 Mar 7.

PMID:
24604592
31.

Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL.

Hohloch K, Zwick C, Ziepert M, Hasenclever D, Kaiser U, Engert A, Höffkes HG, Kroschinsky F, Mesters R, Feller AC, Löffler M, Trümper L, Pfreundschuh M; German High-Grade Non-Hodgkin´s Lymphoma Study Group (DSHNHL).

Springerplus. 2014 Jan 3;3:5. doi: 10.1186/2193-1801-3-5. eCollection 2014 Jan 3.

32.

Modelling lymphoma therapy and outcome.

Roesch K, Hasenclever D, Scholz M.

Bull Math Biol. 2014 Feb;76(2):401-30. doi: 10.1007/s11538-013-9925-3. Epub 2013 Dec 14.

33.

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.

Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Küppers R, Lenze D, Ott G, Pott C, Richter J, Rosenwald A, Szczepanowski M, Schwaenen C, Stein H, Trautmann H, Wessendorf S, Trümper L, Loeffler M, Spang R, Kluin PM, Klapper W, Siebert R; Molecular Mechanisms in Malignant Lymphomas Network Project.

Haematologica. 2014 Apr;99(4):726-35. doi: 10.3324/haematol.2013.091827. Epub 2013 Oct 31.

34.

The EuroNet paediatric hodgkin network - modern imaging data management for real time central review in multicentre trials.

Kurch L, Mauz-Körholz C, Bertling S, Wallinder M, Kaminska M, Marwede D, Tchavdarova L, Georgi TW, Elsner A, Barthel A, Stoevesandt D, Hasenclever D, Sattler B, Sabri O, Körholz D, Kluge R.

Klin Padiatr. 2013 Nov;225(6):357-61. doi: 10.1055/s-0033-1354416. Epub 2013 Oct 28.

PMID:
24166093
35.

Reply to A.S. Reese.

Dörffel W, Lüders H, Claviez A, Hasenclever D, Rühl U.

J Clin Oncol. 2013 Oct 1;31(28):3610-1. doi: 10.1200/JCO.2013.51.7656. Epub 2013 Sep 3. No abstract available.

PMID:
24002521
36.

Detecting Trichinella infections using inverse microscopy and an improved larval counting technique.

Makrutzki G, Riehn K, Hamedy A, Petroff D, Hasenclever D, Meiler H, Lücker E.

J Helminthol. 2014 Dec;88(4):453-8. doi: 10.1017/S0022149X13000424. Epub 2013 Jun 18.

PMID:
23773441
37.

Trichinella detection: identification and statistical evaluation of sources of error in the magnetic stirrer method for pooled sample digestion.

Riehn K, Hasenclever D, Petroff D, Nöckler K, Mayer-Scholl A, Makrutzki G, Lücker E.

Vet Parasitol. 2013 May 20;194(2-4):106-9. doi: 10.1016/j.vetpar.2013.01.031. Epub 2013 Feb 5.

PMID:
23433988
38.

Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.

Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart SH, Lenze D, Szczepanowski M, Paulsen M, Lipinski S, Russell RB, Adam-Klages S, Apic G, Claviez A, Hasenclever D, Hovestadt V, Hornig N, Korbel JO, Kube D, Langenberger D, Lawerenz C, Lisfeld J, Meyer K, Picelli S, Pischimarov J, Radlwimmer B, Rausch T, Rohde M, Schilhabel M, Scholtysik R, Spang R, Trautmann H, Zenz T, Borkhardt A, Drexler HG, Möller P, MacLeod RA, Pott C, Schreiber S, Trümper L, Loeffler M, Stadler PF, Lichter P, Eils R, Küppers R, Hummel M, Klapper W, Rosenstiel P, Rosenwald A, Brors B, Siebert R; ICGC MMML-Seq Project.

Nat Genet. 2012 Dec;44(12):1316-20. doi: 10.1038/ng.2469. Epub 2012 Nov 11.

PMID:
23143595
39.

Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical Hodgkin's lymphoma (HL).

Haase R, Vilser C, Mauz-Körholz C, Hasenclever D, Kluge R, Ruschke K, Borkhardt A, Seeger K, Lehrnbecher T, Kulozik A, Rößler J, Burdach S, Jürgens H, Körholz D.

Klin Padiatr. 2012 Oct;224(6):377-81. doi: 10.1055/s-0032-1323824. Epub 2012 Oct 9.

PMID:
23047832
40.

Impact of age on the efficacy of bone marrow mononuclear cell transplantation in experimental stroke.

Wagner DC, Bojko M, Peters M, Lorenz M, Voigt C, Kaminski A, Hasenclever D, Scholz M, Kranz A, Weise G, Boltze J.

Exp Transl Stroke Med. 2012 Aug 24;4(1):17. doi: 10.1186/2040-7378-4-17.

41.

Remote ischaemic preconditioning for heart surgery. The study design for a multi-center randomized double-blinded controlled clinical trial--the RIPHeart-Study.

Meybohm P, Zacharowski K, Cremer J, Roesner J, Kletzin F, Schaelte G, Felzen M, Strouhal U, Reyher C, Heringlake M, Schön J, Brandes I, Bauer M, Knuefermann P, Wittmann M, Hachenberg T, Schilling T, Smul T, Maisch S, Sander M, Moormann T, Boening A, Weigand MA, Laufenberg R, Werner C, Winterhalter M, Treschan T, Stehr SN, Reinhart K, Hasenclever D, Brosteanu O, Bein B; RIP Heart-Study Investigator Group.

Eur Heart J. 2012 Jun;33(12):1423-6.

PMID:
22880214
42.

Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.

Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, Salaverria I, Hummel M, Loeffler M, Pellissery S, Woessmann W, Schwänen C, Trümper L, Wessendorf S, Spang R, Hasenclever D, Siebert R; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe.

Blood. 2012 Feb 23;119(8):1882-7. doi: 10.1182/blood-2011-10-388470. Epub 2012 Jan 11.

PMID:
22238326
43.

Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report.

Shankar A, Hall GW, Gorde-Grosjean S, Hasenclever D, Leblanc T, Hayward J, Lambilliotte A, Daw S, Perel Y, McCarthy K, Lejars O, Coulomb A, Oberlin WO, Wallace WH, Landman-Parker J.

Eur J Cancer. 2012 Jul;48(11):1700-6. doi: 10.1016/j.ejca.2011.10.018. Epub 2011 Nov 15.

PMID:
22093944
44.

[18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma.

Purz S, Mauz-Körholz C, Körholz D, Hasenclever D, Krausse A, Sorge I, Ruschke K, Stiefel M, Amthauer H, Schober O, Kranert WT, Weber WA, Haberkorn U, Hundsdörfer P, Ehlert K, Becker M, Rössler J, Kulozik AE, Sabri O, Kluge R.

J Clin Oncol. 2011 Sep 10;29(26):3523-8. doi: 10.1200/JCO.2010.32.4996. Epub 2011 Aug 8.

PMID:
21825262
45.

Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults.

Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, Szczepanowski M, Burkhardt B, Trautmann H, Gesk S, Andrusiewicz M, Berger H, Fey M, Harder L, Hasenclever D, Hummel M, Loeffler M, Mahn F, Martin-Guerrero I, Pellissery S, Pott C, Pfreundschuh M, Reiter A, Richter J, Rosolowski M, Schwaenen C, Stein H, Trümper L, Wessendorf S, Spang R, Küppers R, Klapper W, Siebert R; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe; German High-Grade Lymphoma Study Group; Berlin-Frankfurt-Münster-NHL trial group.

Blood. 2011 Jul 7;118(1):139-47. doi: 10.1182/blood-2011-01-330795. Epub 2011 Apr 12.

PMID:
21487109
46.

Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.

Scholz M, Engert A, Franklin J, Josting A, Diehl V, Hasenclever D, Loeffler M; German Hodgkin's Lymphoma Study Group.

Ann Oncol. 2011 Mar;22(3):681-8. doi: 10.1093/annonc/mdq408. Epub 2010 Aug 18.

PMID:
20720088
47.

Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.

Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D.

J Clin Oncol. 2010 Aug 10;28(23):3680-6. doi: 10.1200/JCO.2009.26.9381. Epub 2010 Jul 12.

PMID:
20625128
48.

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, Loeffler M.

J Clin Oncol. 2010 May 10;28(14):2373-80. doi: 10.1200/JCO.2009.26.2493. Epub 2010 Apr 12. Erratum in: J Clin Oncol. 2011 Feb 20;29(6):779.

PMID:
20385988
49.

Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial.

Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY, Beksac M, Hasenclever D, Socié G, Schmitz N.

Lancet Oncol. 2010 Apr;11(4):331-8. doi: 10.1016/S1470-2045(09)70352-3. Epub 2010 Jan 30.

PMID:
20117965
50.

Comparison of estimators for measures of linkage disequilibrium.

Scholz M, Hasenclever D.

Int J Biostat. 2010;6(1):Article 1.

PMID:
21969963

Supplemental Content

Loading ...
Support Center